Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy.
Immunomodulatory effects of low-dose radiotherapy (LD-RT) have been used for the treatment of several benign diseases, including arthrodegenerative and inflammatory pathologies. Graves' disease is an autoimmune disease and radiotherapy (RT) is a therapeutic option for ocular complications. The dose recommended in the clinical practice is 20 Gy (2 Gy/day). We hypothesized that lower doses (<10 Gy total dose, <1 Gy/day) could results in higher efficacy if we achieved anti-inflammatory and immunomodulatory effects of LD-RT. We review current evidence on the effects of RT in the treatment of Graves' disease and the possible use of LD-RT treatment strategy.
Radiation Oncology Department, Hospital Universitari Sant Joan de Reus, Institut d'Investigacions Sanitàries Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Tarragona, Spain.
Meritxell
M
Arenas
Radiation Oncology Department, Complejo Hospitalario Universitario Albacete (CHUA), Spain.
Sebastià
S
Sabater
Radiation Oncology Department, Hospital Universitario Dr Negrín, Universidad Las Palmas de Gran Canaria (LPGC), Las Palmas de Gran Canaria, Spain.
Pedro Lara
PL
Jiménez
Radiation Oncology Department, Hospital Universitari Clínic de Barcelona, Spain.
Àngels
À
Rovirosa
Radiation Oncology Department, Hospital Universitari Clínic de Barcelona, Spain.
Albert
A
Biete
Laboratory of Toxicology and Environmental Health, School of Medicine, IISPV, URV, Reus, Spain.
Victoria
V
Linares
Laboratory of Toxicology and Environmental Health, School of Medicine, IISPV, URV, Reus, Spain.
Montse
M
Belles
Gastroenterology Department, Hospital Universitari Clínic de Barcelona, Spain.
Julià
J
Panés
Graves’ ophthalmopathy; Low-dose radiotherapy; Radiotherapy for benign disease